ArticleCurrent microbiology2026
Biogenic Silver Nanoparticles: An Antibacterial and Antibiofilm Approach to Control Carbapenem-Resistant Klebsiella pneumoniae.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infections.Archives of microbiology · 2026Review
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing resistance of Klebsiella pneumoniae to antibiotics, particularly carbapenems, underscores the urgent need for alternative antimicrobial strategies. This study aimed to evaluate the antimicrobial and antibiofilm activity of biogenic silver nanoparticles (Bio-AgNPs), synthesized using Trichilia catigua extract and to investigate their mechanism of action on bacterial cells. The antimicrobial efficacy of Bio-AgNPs was assessed by determining the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and through susceptibility assays, time-kill analysis, flow cytometry, and electron microscopy. Bio-AgNPs exhibited strong antibacterial activity against all tested K. pneumoniae strains, with MICs ranging from 0.49 to 15.62 µg/mL. Eradication of biofilms required concentrations 16 to 64 times higher than those effective against planktonic cells, highlighting the protective nature of biofilm matrix. Time-kill assays showed a concentration-dependent bactericidal effect, with 4xMIC rapidly eliminating viable cells. Flow cytometry indicated membrane destabilization, increased fluidity at lower concentrations, and extensive structural damage at higher concentrations. Although lipid peroxidation and reactive oxygen species (ROS) were detected, they were not statistically significant, suggesting that membrane disruption is the primary bactericidal mechanism. Electron microscopy corroborated the structural disintegration of both bacterial cells and biofilms after treatment. Bio-AgNPs demonstrated potent antimicrobial and antibiofilm effects against multidrug-resistant K. pneumoniae, with membrane damage as the main mechanism of action. These results support the potential application of Bio-AgNPs as a therapeutic alternative for biofilm-associated infections. This study highlights the antibacterial and anti-biofilm potential of biogenic silver nanoparticles (Bio-AgNPs) as an effective tool against multidrug-resistant Klebsiella pneumoniae, with efficancy against both free-living cells and structured biofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.